ArriVent BioPharma, Inc. (AVBP) vs Bicara Therapeutics Inc. Common Stock (BCAX)
A side-by-side comparison of ArriVent BioPharma, Inc. and Bicara Therapeutics Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$15.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
BCAX
Bicara Therapeutics Inc. Common Stock
$16.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AVBP vs BCAX
growth of $100 · dividends reinvested · last 2yAVBP +19.8% (+9.4%/yr)BCAX -26.1% (-14.1%/yr)AVBP compounded faster over this window
AVBP BCAX
AVBP vs BCAX: by the numbers
- •BCAX is the larger company ($1.09B vs $703M market cap).
Metrics side by side
Valuation
| Metric | AVBP | BCAX |
|---|---|---|
| P/B ratio | 1.92 | 2.32 |
Profitability
| Metric | AVBP | BCAX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -44.63% | -39.54% |
| ROIC | -47.96% | -42.98% |
Go deeper
Dig into the metrics
ArriVent BioPharma ROEBicara Therapeutics Inc. Common Stock ROEArriVent BioPharma operating marginBicara Therapeutics Inc. Common Stock operating marginArriVent BioPharma revenue growthBicara Therapeutics Inc. Common Stock revenue growthArriVent BioPharma free cash flowBicara Therapeutics Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.